Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals, which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. (Image Credit: Twitter)
Following is a summary of current science news briefs.
Akcea Therapeutics genetic disease treatment gets FDA approval
Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals, which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy.
(With inputs from agencies.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{ImageCopyright}}
{{Disclaimer}}
{{/Disclaimer}}